What is the recommended dose of ursodeoxycholic acid (UDCA) for an adult with cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Dose of Ursodeoxycholic Acid in Adults with Cirrhosis

For adults with cirrhosis due to primary biliary cholangitis (PBC), ursodeoxycholic acid should be dosed at 13-15 mg/kg/day, divided into 2-3 doses daily. 1, 2

Dosing Algorithm

Standard Dosing for PBC-Related Cirrhosis

  • Dose: 13-15 mg/kg/day divided into 2-3 daily doses
  • This is first-line therapy and should be initiated at diagnosis 2
  • Continue indefinitely, even if alkaline phosphatase remains elevated, as survival benefits persist 1, 2

Key Implementation Points

Do NOT exceed 15 mg/kg/day:

  • Increasing beyond this dose does not improve biochemical response or symptoms 1, 2
  • Higher doses have not demonstrated additional benefit in clinical trials 3

Timing of response assessment:

  • Monitor liver enzymes every 3 months during the first year 2
  • Assess biochemical response at 6-12 months after initiation 2
  • For high-risk patients (liver stiffness ≥10 kPa, age <62 years), assess response as early as 6 months 2

Evidence Supporting This Dose

The 13-15 mg/kg/day dosing is supported by the most recent 2026 AGA/AASLD guidelines with strong recommendation and moderate certainty of evidence 1, 2. This dose has been shown to:

  • Improve liver biochemistries (reduces bilirubin by ~8.69 μmol/L and alkaline phosphatase by ~257 U/L) 1
  • Delay histologic progression (absolute risk reduction of 145 fewer patients with progression per 1000 treated) 1
  • Improve transplant-free survival when initiated at early disease stages 4

Critical Caveats

This dosing applies specifically to PBC-related cirrhosis. The evidence provided does not support UDCA use for cirrhosis from other etiologies (e.g., viral hepatitis, alcohol-related, NASH). The FDA label 5 lists different dosing for gallstone dissolution (8-10 mg/kg/day) and prevention (600 mg/day), which are not applicable to cirrhosis management.

Do not discontinue UDCA if alkaline phosphatase remains elevated - the drug still provides sustained survival benefits even without complete biochemical normalization 1, 2. In such cases, consider adding second-line therapy (PPAR agonists like elafibranor 80 mg/day or seladelpar 10 mg/day) rather than stopping UDCA 2.

Inadequate response is defined as: failure to achieve alkaline phosphatase <1.5-1.67 times upper limit of normal AND normal total bilirubin at 12 months 2. This triggers consideration for add-on therapy, not dose escalation.

Practical Dosing Example

For a 70 kg adult with PBC-related cirrhosis:

  • Target dose: 910-1050 mg/day (13-15 mg/kg × 70 kg)
  • Practical dosing: 900-1050 mg/day divided into 2-3 doses
  • This aligns with research showing 900 mg/day (approximately 13.5 mg/kg/day for average-weight patients) as optimal 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.